| Mrs Carmen J Negron, MD | |
|
Ave De Diego #201, Plaza San Fco Ofic #30, San Juan, PR 00927 | |
| (787) 751-3587 | |
| (787) 753-4631 |
| Full Name | Mrs Carmen J Negron |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 50 Years |
| Location | Ave De Diego #201, San Juan, Puerto Rico |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821013335 | NPI | - | NPPES |
| 27193 | Other | TRIPLES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 004746 (Puerto Rico) | Primary |
| 2085U0001X | Radiology - Diagnostic Ultrasound | 004746 (Puerto Rico) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Roberto J Sein And Rafael M Rivera Ptr | 8325125909 | 6 |
News Archive
WellCare Health Plans, Inc. today announced that the Centers for Medicare & Medicaid Services ("CMS") released the Company from the previously disclosed sanctions, except as noted below. The Company will resume marketing its Medicare Prescription Drug Plans and Medicare Advantage coordinated care plans over the coming days.
Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
A newly identified regulatory process affecting the biology of immune system T cells should give scientists new approaches to explore the causes of autoimmunity and immune deficiency diseases.
Texting while driving can be a deadly combination for teenagers. Yet, new data released today reveal that the dangers of excessive texting among teens are not limited to the road. Hyper-texting and hyper-networking are now giving rise to a new health risk category for this age group.
› Verified 6 days ago
| Entity Name | Roberto J Sein & Rafael M Rivera Ptr |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336202753 PECOS PAC ID: 8325125909 Enrollment ID: O20080407000423 |
News Archive
WellCare Health Plans, Inc. today announced that the Centers for Medicare & Medicaid Services ("CMS") released the Company from the previously disclosed sanctions, except as noted below. The Company will resume marketing its Medicare Prescription Drug Plans and Medicare Advantage coordinated care plans over the coming days.
Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
A newly identified regulatory process affecting the biology of immune system T cells should give scientists new approaches to explore the causes of autoimmunity and immune deficiency diseases.
Texting while driving can be a deadly combination for teenagers. Yet, new data released today reveal that the dangers of excessive texting among teens are not limited to the road. Hyper-texting and hyper-networking are now giving rise to a new health risk category for this age group.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Carmen J Negron, MD 11 Calle Costa Azul, Paseo Las Brisqs, San Juan, PR 00926 Ph: (787) 760-4232 | Mrs Carmen J Negron, MD Ave De Diego #201, Plaza San Fco Ofic #30, San Juan, PR 00927 Ph: (787) 751-3587 |
News Archive
WellCare Health Plans, Inc. today announced that the Centers for Medicare & Medicaid Services ("CMS") released the Company from the previously disclosed sanctions, except as noted below. The Company will resume marketing its Medicare Prescription Drug Plans and Medicare Advantage coordinated care plans over the coming days.
Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
A newly identified regulatory process affecting the biology of immune system T cells should give scientists new approaches to explore the causes of autoimmunity and immune deficiency diseases.
Texting while driving can be a deadly combination for teenagers. Yet, new data released today reveal that the dangers of excessive texting among teens are not limited to the road. Hyper-texting and hyper-networking are now giving rise to a new health risk category for this age group.
› Verified 6 days ago
Bernardo Jose Marques Diaz, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 310 Lomas Verdes Ave. Suite 208, San Juan, PR 00927 Phone: 787-751-3150 Fax: 787-767-0338 | |
Dr. Roberto F Marchan, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 271 Ave J T Pinero, San Juan, PR 00927 Phone: 787-759-9660 Fax: 787-759-9660 | |
Wilmarie Rivera Hernandez, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 617 Calle Manuel Pavia, San Juan, PR 00909 Phone: 787-625-1446 | |
Dr. Wilma Rodriguez Mojica, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: Fernandez Street No. 6 , Third Floor, San Juan, PR 00918 Phone: 787-763-6336 Fax: 787-763-6207 | |
Luis Garcia Paredes, Radiology Medicare: Accepting Medicare Assignments Practice Location: 1462 Calle Prof Augusto Rodriguez, San Juan, PR 00909 Phone: 787-641-1616 | |
Mr. Roberto J Sein, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: Ave De Diego 201, Plaza San Fco Ofic #30, San Juan, PR 00927 Phone: 787-751-5587 Fax: 787-753-4631 | |
Dr. Ivonne Marquez Valencia, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 258 Calle San Jorge, San Juan, PR 00912 Phone: 787-727-1000 |